CA-LASERFICHE
8.6.2022 15:02:06 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has launched the Laserfiche Solution Marketplace , a publicly-accessible collection of solution templates to help jumpstart process automation and digital transformation. Today, Laserfiche has begun accepting solution templates from users to expand the marketplace even further.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005029/en/
The Laserfiche Solution Marketplace helps organizations address digital transformation needs and accelerate innovation enterprise-wide by taking a low-code approach to process automation and integration. Users can build and deploy their own automated workflows or connect Laserfiche to other applications faster using pre-built solutions, which follow industry-vetted designs and best practices.
“To make process automation easier and more accessible for our global community, Laserfiche is focused on creating intuitive and scalable process automation applications,” said Laserfiche Director of Product Management Justin Pava. “Developed by Laserfiche users and experts, these solution templates enable organizations to build on existing best practices, industry expertise and product knowledge, and tailor solutions to fit their unique needs.”
The Laserfiche Solution Marketplace currently contains more than 100 solution templates that address both common business processes and individual industry or organization needs. Commonly deployed solution templates include:
- New hire onboarding
- Accounts payable – purchase order requisition
- Contract management
- Federal Assistance Program solution for governments
- New account opening for financial services firms
- HEERF student aid grant applications for institutions of higher education
- The full list can be found here
Users can also easily preview solutions before downloading, and view lists of newly added, most popular and trending processes. These features are aimed at sparking more ideas, and further empowering IT teams and citizen developers to drive digital transformation across their organizations.
“As a large, growing school district, we are always looking to become more efficient and to reimagine our processes in order to better serve our students and their families,” said John Rokenbrod, software and records analyst and records management officer at Bryan Independent School District. “Having access to prebuilt templates with workflows, forms and even integrations that we can customize to fit our needs provides a tremendous amount of inspiration and saves us from having to reinvent the wheel each time we need a solution. The Laserfiche Solution Marketplace provides the support for our digital projects that allows us to remain focused on creating a great work environment for our staff and the best possible experience for our students.”
By opening up the marketplace for solution template submissions from users, Laserfiche aims to expand the breadth of offerings in the marketplace even further. At the same time, Laserfiche customers will contribute to the strength of an innovative user community and be empowered to build on the successes of other Laserfiche process builders and innovators.
To learn more about solution templates and how to submit your own, visit the Laserfiche Solution Marketplace: https://marketplace.laserfiche.com/ .
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry—including government, education, financial services, healthcare and manufacturing—use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005029/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom